Q-omics provides the consensus-scored TMEM178B profile across patient tissues and cancer cell-line models. TMEM178B expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, TMEM178B is differentially expressed in 14, with the highest sampling consensus in KIRP. Additionally, TMEM178B RNA expression shows 18,529 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and KIRP as cancer lineages where TMEM178B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM178B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM178B survival associations across molecular data types. TMEM178B RNA expression shows survival associations in the most cancer types (20), followed by mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM178B RNA expression–survival associations across cancer types. High TMEM178B expression shows unfavorable associations in UVM, UCEC and THYM, but favorable associations in PAAD, SKCM and LUAD. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for TMEM178B RNA expression.
This table summarizes TMEM178B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for TMEM178B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM178B shows lower tumor expression in THCA, KICH and HNSC and higher tumor expression in KIRP, COAD and LIHC. The KIRP box plot shows higher TMEM178B RNA expression in tumor versus normal tissue (log2 FC = +2.164, t-test p < 0.001).
This table shows molecular features associated with TMEM178B in patient tissues and cancer cell lines. In patient samples, TMEM178B shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM178B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BONE and BREAST.
